Cristiana Guiducci
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Cristiana Guiducci has a total of 61 co-authors. Here are the top co-authors by number of shared publications:
- Albert Candia
19IGM Biosciences, Mountain View, California
10 shared publications - Antoni Ribas
Department of Medicine, Division of Hematology and Oncology, University of California, Los Angeles, Los Angeles, USA
10 shared publications - Asim Amin
Department of Solid Tumor and Investigational Therapeutics, Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, North Carolina
10 shared publications - Christopher D. Lao
Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan
10 shared publications - Christopher Hoimes
Department of Medicine Duke Cancer Institute Durham North Carolina USA
10 shared publications - Ehtesham Abdi
14Tweeds Valley Hospital, Cudgen, Australia
10 shared publications
Latest Publications
- Open Access
Bexobrutideg: A Selective, Catalytic Degrader of Bruton’s Tyrosine Kinase Overcomes Inhibitor Resistance and Suppresses Autoantibody-Mediated Disease
Bruton’s tyrosine kinase (BTK) transduces B-cell receptor (BCR), Toll-like receptor (TLR), and Fc receptor (FcR) signaling, and overactivation of these pathways drives B-cell malignancies and antibody-mediated autoimmune disease. Small molecule inhibitors block the enzymatic functions of BTK, but this inhibition is undermined by resistance mutations, several of which abolish BTK’s kinase activity yet promote oncogenic signaling through BTK scaffolding functions. We report the discovery and characterization of bexobrutideg (NX-5948), a heterobifunctional degrader that recruits cereblon (CRBN) to selectively degrade BTK while sparing molecular glue neosubstrates. We demonstrate that bexobrutideg acts catalytically, degrading thousands of copies of BTK per molecule per hour, and this event-driven pharmacology renders it resilient to mutations that confer resistance to both covalent- and noncovalent-inhibitors. Bexobrutideg is orally bioavailable, driving deep and durable BTK degradation across species. Bexobrutideg demonstrates strong efficacy in wild-type and ibrutinib-resistant lymphoma models and robustly suppresses pathway activation in models of autoimmune disease.
Open AccessBexobrutideg: A Selective, Catalytic Degrader of Bruton’s Tyrosine Kinase Overcomes Inhibitor Resistance and Suppresses Autoantibody-Mediated Disease
Bruton’s tyrosine kinase (BTK) transduces B-cell receptor (BCR), Toll-like receptor (TLR), and Fc receptor (FcR) signaling, and overactivation of these pathways drives B-cell malignancies and antibody-mediated autoimmune disease. Small molecule inhibitors block the enzymatic functions of BTK, but this inhibition is undermined by resistance mutations, several of which abolish BTK’s kinase activity yet promote oncogenic signaling through BTK scaffolding functions. We report the discovery and characterization of bexobrutideg (NX-5948), a heterobifunctional degrader that recruits cereblon (CRBN) to selectively degrade BTK while sparing molecular glue neosubstrates. We demonstrate that bexobrutideg acts catalytically, degrading thousands of copies of BTK per molecule per hour, and this event-driven pharmacology renders it resilient to mutations that confer resistance to both covalent- and noncovalent-inhibitors. Bexobrutideg is orally bioavailable, driving deep and durable BTK degradation across species. Bexobrutideg demonstrates strong efficacy in wild-type and ibrutinib-resistant lymphoma models and robustly suppresses pathway activation in models of autoimmune disease.
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti–PD-1 Treatment-Naïve Advanced Melanoma
Table S3 reports PFS for patients with anti–PD-1/PD-L1–naive melanoma who received nelitolimod 2 mg or 8 mg and pembrolizumab 200 mg (intention-to-treat).
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti–PD-1 Treatment-Naïve Advanced Melanoma
Table S3 reports PFS for patients with anti–PD-1/PD-L1–naive melanoma who received nelitolimod 2 mg or 8 mg and pembrolizumab 200 mg (intention-to-treat).
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti–PD-1 Treatment-Naïve Advanced Melanoma
Figure S1 shows the treatment schema with nelitolimod 2 mg or 8 mg and pembrolizumab 200 mg. Nelitolimod was administered weekly for 4 weeks, followed by one dose every 3 weeks for up to 22 doses.
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti–PD-1 Treatment-Naïve Advanced Melanoma
Figure S1 shows the treatment schema with nelitolimod 2 mg or 8 mg and pembrolizumab 200 mg. Nelitolimod was administered weekly for 4 weeks, followed by one dose every 3 weeks for up to 22 doses.
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti–PD-1 Treatment-Naïve Advanced Melanoma
Figure S2 shows detailed response and treatment duration data for patients with anti–PD-1/PD-L1–naive melanoma treated with nelitolimod 2 mg plus pembrolizumab 200 mg. The figure illustrated patterns of tumor response over time.
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti–PD-1 Treatment-Naïve Advanced Melanoma
Figure S2 shows detailed response and treatment duration data for patients with anti–PD-1/PD-L1–naive melanoma treated with nelitolimod 2 mg plus pembrolizumab 200 mg. The figure illustrated patterns of tumor response over time.
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti–PD-1 Treatment-Naïve Advanced Melanoma
Figure S3 shows best percentage changes from baseline in target lesion size, grouped by PD-L1 status, for patients treated with nelitolimod 8 mg plus pembrolizumab 200 mg. The plot highlights greater tumor shrinkage in patients with PD-L1–positive tumors
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti–PD-1 Treatment-Naïve Advanced Melanoma
Figure S3 shows best percentage changes from baseline in target lesion size, grouped by PD-L1 status, for patients treated with nelitolimod 8 mg plus pembrolizumab 200 mg. The plot highlights greater tumor shrinkage in patients with PD-L1–positive tumors
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti–PD-1 Treatment-Naïve Advanced Melanoma
Figure S6 shows transcriptomic data from paired tumor biopsies collected at baseline and on therapy from patients treated with nelitolimod 2 mg plus pembrolizumab 200 mg. The figure displays consistent and durable increases in the expression of gene signatures representing immune cell density and upregulation of functional signatures.
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti–PD-1 Treatment-Naïve Advanced Melanoma
Figure S6 shows transcriptomic data from paired tumor biopsies collected at baseline and on therapy from patients treated with nelitolimod 2 mg plus pembrolizumab 200 mg. The figure displays consistent and durable increases in the expression of gene signatures representing immune cell density and upregulation of functional signatures.
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti–PD-1 Treatment-Naïve Advanced Melanoma
Table S1 shows additional exclusion criteria of this study.
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti–PD-1 Treatment-Naïve Advanced Melanoma
Table S1 shows additional exclusion criteria of this study.
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti–PD-1 Treatment-Naïve Advanced Melanoma
Figure S4 shows best percentage changes from baseline in target lesion size for patients treated with nelitolimod 2 mg or 8 mg plus pembrolizumab 200 mg. The plot illustrates the depth of tumor response across both dosing groups.
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti–PD-1 Treatment-Naïve Advanced Melanoma
Figure S4 shows best percentage changes from baseline in target lesion size for patients treated with nelitolimod 2 mg or 8 mg plus pembrolizumab 200 mg. The plot illustrates the depth of tumor response across both dosing groups.
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti–PD-1 Treatment-Naïve Advanced Melanoma
Table S2 describes the representativeness of study participants.
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti–PD-1 Treatment-Naïve Advanced Melanoma
Table S2 describes the representativeness of study participants.
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti–PD-1 Treatment-Naïve Advanced Melanoma
Figure S5 shows Kaplan-Meier curves depicting progression-free survival for patients treated with nelitolimod 2 mg or 8 mg in combination with pembrolizumab 200 mg. The figure illustrates time-to-event data for each dose group.
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti–PD-1 Treatment-Naïve Advanced Melanoma
Figure S5 shows Kaplan-Meier curves depicting progression-free survival for patients treated with nelitolimod 2 mg or 8 mg in combination with pembrolizumab 200 mg. The figure illustrates time-to-event data for each dose group.